Single and combined effects of plant‐derived and synthetic cannabinoids on cognition and cannabinoid‐associated withdrawal signs in mice

Myers, Alyssa M; Siegele, Patrick B; Foss, Jeffrey; Tuma, Ronald F.; Ward, Sara Jane

doi:10.1111/bph.14147

Cited by 21 publications

(22 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical data on THC prove anticonvulsant ( 22 ), as well as proconvulsive ( 23 ) and adverse effects on neurocognitive functioning ( 24 ). Clinical data show adverse structural and functional effects resulting from long term THC use ( 25 , 26 ).…”

Section: Discussionmentioning

confidence: 99%

Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey

et al. 2018

View full text Add to dashboard Cite

Background: The interest in cannabidiol (CBD) for treatment of epilepsy has been increasing over the last years. However, practitioner's attitudes concerning the use of CBD for epilepsy treatment appears to be divided and data about its clinical use in daily practice are not available.Objective: To improve the knowledge about the current use of CBD amongst European practitioners treating children and adolescents for epilepsy.Methods: Cross-sectional survey using an open-access online questionnaire for physicians treating children or adolescents for epilepsy within eight European countries from December 2017 to March 2018.Results: One-hundred fifty-five physicians participated in the survey. CBD is increasingly used by 45% (69/155) of participants, treating a mean (range) number of 3 (1–35) with CBD. Only 48% of the participants prescribing CBD are exclusively using purified CBD to treat children and adolescents with epilepsy, the remainder also applies preparations containing delta9-tetrahydrocannabinol (THC). Reported daily CBD doses range from < 10 to 50 mg/kg body weight. Management of CBD therapy in regard of monitoring side effects and adjusting concomitant therapy differs widely amongst participants. Their primary objective for commencing CBD is improving patient's quality of life. Participants frequently receive inquiries about CBD treatment but only 40% may actively suggest CBD as a treatment option. Of the 85 participants currently not using CBD for epilepsy treatment, 70% would consider using CBD if available in their country of practice or given the opportunity to become familiar with this treatment option.Conclusions: CBD is increasingly used by participating physicians but individual experience remains limited. There are very diverse opinions about the use of CBD to treat epilepsy in children and adolescents and widely differing views on how to manage the CBD treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Also, in alcohol-and cocaine-dependent rats CBD attenuated the drug seeking behaviour without inducing tolerance, sedation, or interfering with normal motivated behaviour (Gonzalez-Cuevas et al, 2018). In rodents, CBD chronic administration did not induce dependence whilst the long-term co-administration of equal ratios of CBD and THC did not reduce THC dependence levels (Myers et al, 2018). In evaluating the role of oral CBD in frequent, healthy, cannabis users, Babalonis et al (2017) found that CBD at 200, 400, 800 mg once daily (OD) was not associated with abuse when compared to oral placebo and active marijuana products with high levels of THC up to 5.3-5.8%.…”

Section: Introductionmentioning

confidence: 94%

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

et al. 2019

View full text Add to dashboard Cite

Cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different activity compared with the psychotomimetic THC. Most typically, CBD is reported to be used in some medical conditions, including chronic pain. Conversely, the main aim of this systematic review is to assess and summarise the available body of evidence relating to both efficacy and safety of CBD as a treatment for psychiatric disorders, alone and/or in combination with other treatments. Eligible studies included randomized controlled trials (RCT) assessing the effect of CBD in a range of psychopathological conditions, such as substance use; psychosis, anxiety, mood disturbances, and other psychiatric (e.g., cognitive impairment; sleep; personality; eating; obsessive-compulsive; post-traumatic stress/PTSD; dissociative; and somatic) disorders. For data gathering purposes, the PRISMA guidelines were followed. The initial search strategy identified some n=1,301 papers; n=190 studies were included after the abstract's screening and n=27 articles met the inclusion criteria. There is currently limited evidence regarding the safety and efficacy of CBD for the treatment of psychiatric disorders. However, available trials reported potential therapeutic effects for specific psychopathological conditions, such as substance use disorders, chronic psychosis, and anxiety. Further large-scale RCTs are required to better evaluate the efficacy of CBD in both acute and chronic illnesses, special categories, as well as to exclude any possible abuse liability.

show abstract

“…CB1R antagonist (SR141716) administration precipitated withdrawal signs in chronically THC-treated C57BL/6J mice and they were not attenuated by CBD. However, the lack of CBD-induced withdrawal signs or cognitive performance impairment, together with the robust anxiolytic effect led the authors to conclude that CBD as a monotherapy might be a safer pharmacological agent for the treatment of several disorders ( Myers et al, 2019 ).…”

Section: Cbd As a Potential New Pharmacological Tool For The Treatment Of Sudmentioning

confidence: 99%

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

et al. 2021

View full text Add to dashboard Cite

Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These facts hamper the clinical outcome and the quality of life of the patients supporting the importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant for the management of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s, or Alzheimer’s diseases. Furthermore, there is a large body of evidence pointing out that CBD improves cognition, neurogenesis and presents anxiolytic, antidepressant, antipsychotic, and neuroprotective effects suggesting potential usefulness for the treatment of neuropsychiatric diseases and SUD. Here we review preclinical and clinical reports regarding the effects of CBD on the regulation of the reinforcing, motivational and withdrawal-related effects of different drugs of abuse such as alcohol, opioids (morphine, heroin), cannabinoids, nicotine, and psychostimulants (cocaine, amphetamine). Furthermore, a special section of the review is focused on the neurobiological mechanisms that might be underlying the ‘anti-addictive’ action of CBD through the regulation of dopaminergic, opioidergic, serotonergic, and endocannabinoid systems as well as hippocampal neurogenesis. The multimodal pharmacological profile described for CBD and the specific regulation of addictive behavior-related targets explains, at least in part, its therapeutic effects on the regulation of the reinforcing and motivational properties of different drugs of abuse. Moreover, the remarkable safety profile of CBD, its lack of reinforcing properties and the existence of approved medications containing this compound (Sativex®, Epidiolex®) increased the number of studies suggesting the potential of CBD as a therapeutic intervention for SUD. The rising number of publications with substantial results on the valuable therapeutic innovation of CBD for treating SUD, the undeniable need of new therapeutic agents to improve the clinical outcome of patients with SUD, and the upcoming clinical trials involving CBD endorse the relevance of this review.

show abstract

Single and combined effects of plant‐derived and synthetic cannabinoids on cognition and cannabinoid‐associated withdrawal signs in mice

Abstract: CBD as a monotherapy may prove to be a safer pharmacological agent, than CB receptor agonists alone or in combination with CBD, for the treatment of several disorders.

Cited by 21 publications

References 69 publications

Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey

Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

Contact Info

Product

Resources

About